KaloBios Pharma's Phase 2 Study Of KB003 Fails To Meet Primary Endpoint

(RTTNews) - KaloBios Pharmaceuticals, Inc. (KBIO) Wednesday said its Phase 2 study of KB003, its anti-GM-CSF monoclonal antibody indicated in the treatment of patients with severe asthma, did not meet its primary clinical endpoint of improvement in FEV1, a measurement of pulmonary function.

"The results of this study replicate the effects seen in our earlier Phase 1/2 study in eosinophilic and highly reversible patients. Unfortunately the drug effect did not include improvement in exacerbations and ACQ, nor was the FEV1 improvement seen in the broader patient population evaluated in this study," said Nestor Molfino, Chief Medical Officer.

The company said it is discontinuing clinical development of KB003 in severe asthma, and planning to refocus on advancing its products like KB001-A, KB004 etc.